Using advanced MRI to assess treatment response in pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in predicting treatment response in patients with pancreatic ductal adenocarcinoma (PDA), including both locally advanced and metastatic cases. The study aims to measure changes in tumor metabolism using this experimental imaging technique before and after treatment initiation. By comparing these metabolic changes to standard imaging results, researchers hope to determine if this new approach provides better predictive value for treatment outcomes. The study includes various cohorts to assess different aspects of tumor response and metabolism over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must be 18 years or older.
* Histological or cytological confirmation of pancreatic ductal adenocarcinoma (PDA).
* Locally advanced or metastatic disease.
* At least one target lesion in the abdomen measuring ≥ 1centimeter (cm), according to RECIST v1.1.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 (Karnofsky ≥ 50%)
* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or endpoints of this study are eligible.
* Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

* Participants unwilling or unable to undergo magnetic resonance (MR) imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
* Poorly controlled hypertension, defined as either systolic \> 170 or diastolic \> 110. The addition of anti-hypertensives to control blood pressure is allowed for eligibility determination.
* Congestive Heart Failure ≥ Class III.
* Participants who are pregnant.
* Individuals of childbearing potential must agree to undergo a urine pregnancy test prior to participating in the study scans. Pregnant individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn child secondary to administration of HP 13C pyruvate to the study participant. A female is considered to not be of childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (\>= 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries).
* Participants who are breastfeeding/chestfeeding. Breastfeeding/chestfeeding individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to administration of HP 13C pyruvate to the study participant. Breastfeeding/chestfeeding should be discontinued before administration of HP 13C pyruvate.
* Known hypersensitivity to HP 13C pyruvate or any of its excipients.
* Participants with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study procedures

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Zhen Wang, MD — University of California, San Francisco
• Study coordinator: Louise Magat
• Email: Louise.Magat@ucsf.edu
• Phone: (415) 502-1822

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ctDNA to guide earlier switching from first-line mFOLFIRINOX in metastatic pancreatic cancer

  This will test whether a blood test (ctDNA) can tell if people with metastatic pancreatic cancer are not responding to first-line mFOLFIRINOX soon enough to switch therapies earlier than standard imaging.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07096362

• OMO-103 for advanced or metastatic pancreatic ductal adenocarcinoma

  This trial tests an experimental IV drug called OMO-103 to see if it changes tumor cells in adults with locally advanced or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT07089940

• Tumor DNA and protein testing to understand pancreatic cancer treatment response

  This trial will test whether measuring tumor DNA and proteins from people with resectable or locally advanced pancreatic ductal adenocarcinoma can be done quickly enough and provide information about how their cancer responds to standard chemotherapy.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06574620

• Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors

  This study is testing new RAS(ON) inhibitors combined with standard treatments to see if they can help people with certain types of gastrointestinal cancers that have RAS mutations.

  Recruiting at 32 sites Phase 1/2 Revolution Medicines, Inc. · Chandler, Arizona and 31 other locations · NCT06445062

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

• Targeted therapy for pancreatic cancer using new drugs

  This study is testing new targeted therapies for pancreatic cancer to see how well they work and if they are safe for patients at different stages of the disease.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT04005690

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.